Behavior

Cadence and NVIDIA Unveil Groundbreaking Generative AI and Accelerated Compute-Driven Innovations

Retrieved on: 
Monday, March 18, 2024
Software, Mobile, Wireless, Hardware, Pharmaceutical, Electronic Design Automation, Data Management, Consumer Electronics, Technology, Artificial Intelligence, Environment, Semiconductor, Health Technology, Health, GPU, Digital, Acceleration, Drug discovery, Partnership, EDA, Society, HPC, CDNS, AI, Cadence Design Systems, Orion, Behavior, Therapy, NVIDIA, PPA, Nvidia Omniverse, Peptide, Video game

Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced an expansion of its multi-year collaboration with NVIDIA across EDA, system design and analysis, digital biology and AI with the unveiling of two transformative solutions to reinvent design using accelerated computing and generative AI.

Key Points: 
  • Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced an expansion of its multi-year collaboration with NVIDIA across EDA, system design and analysis, digital biology and AI with the unveiling of two transformative solutions to reinvent design using accelerated computing and generative AI.
  • Second, the companies are collaborating on generative AI to dramatically accelerate approaches to drug discovery.
  • Cadence’s cloud-native molecular design platform Orion® will now be supercharged with NVIDIA’s generative AI tool, NVIDIA BioNeMo™ , and NVIDIA microservices for drug discovery to broaden therapeutic design capabilities and shorten time to trusted results.
  • Together, NVIDIA and Cadence are leading the AI revolution.”
    “Digital twins will transform manufacturing, drug discovery and countless other industries,” said Jensen Huang, founder and CEO of NVIDIA.

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Retrieved on: 
Thursday, March 14, 2024
Mental Health, Finance, FDA, Clinical Trials, Professional Services, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Depression, Week, DEA, BTD, Inc., MDD, Patient, Accelerated approval (FDA), DSM-IV codes, Suicidal ideation, Behavior, Priority review, Drug development, Major depressive disorder, Pharmaceutical industry

The Company has received minutes from its End-of-Phase-2 meeting with the FDA and reached alignment on its Phase 3 program design.

Key Points: 
  • The Company has received minutes from its End-of-Phase-2 meeting with the FDA and reached alignment on its Phase 3 program design.
  • The Company intends to commence enrollment for the multinational, multisite Phase 3 program in mid-year 2024.
  • The Company has engaged Worldwide Clinical Trials (“Worldwide”), a global, full-service contract research organization with deep expertise managing clinical trials for mental health conditions, including major depressive disorder.
  • Having aligned on key features of the pivotal program, we look forward to initiating a multisite, multinational Phase 3 program around mid-year,” said Doug Drysdale, Chief Executive Officer of Cybin.

Vida Health's Obesity Solutions with Integrated Prescribing Capabilities Shows Promising Results

Retrieved on: 
Thursday, March 14, 2024
General Health, Diabetes, Health, Pharmaceutical, Cardiology, Kidney disease, Patient, Obesity, Behavior, Heart, Medical imaging

Vida Health , a leading virtual cardiometabolic clinic, is proud to announce encouraging preliminary results from its innovative virtual obesity solution with integrated prescribing capabilities.

Key Points: 
  • Vida Health , a leading virtual cardiometabolic clinic, is proud to announce encouraging preliminary results from its innovative virtual obesity solution with integrated prescribing capabilities.
  • Part of Vida Health's comprehensive approach to weight management, Vida’s obesity solution integrates personalized lifestyle interventions, medical nutrition therapy, and, when necessary, pharmacotherapy to tackle obesity.
  • "Our early observations are incredibly promising," said Dr. Richard Frank, Chief Medical Officer at Vida Health.
  • "We’re dedicated to transforming obesity care by prioritizing interventions that patients can sustain long-term," stated Joe Murad, CEO of Vida Health.

InfluxData Collaborating with AWS to Bring InfluxDB and Time Series Analytics to Developers Around the World

Retrieved on: 
Friday, March 15, 2024
Networks, Internet, Data Management, Technology, Software, Cloud, InfluxDB, Serverless computing, Amazon Web Services, Database, CLI, Information technology, Amazon Virtual Private Cloud, SQL, Amazon, Environment, Data analysis, Organizational founder, OSS, Artificial intelligence, CDK, AWS, Industrial, Behavior, API, Self-management, Veeam, Online shopping

Making InfluxDB a preferred AWS time series database signifies InfluxData’s category leadership and the high-growth market for time series databases to power real-time analytics and artificial intelligence (AI) training models.

Key Points: 
  • Making InfluxDB a preferred AWS time series database signifies InfluxData’s category leadership and the high-growth market for time series databases to power real-time analytics and artificial intelligence (AI) training models.
  • By working with InfluxData, AWS developers now have a simple way to manage and derive value from time series data within the AWS Management Console.
  • In the future, Amazon Timestream for InfluxDB will expand to offer additional InfluxDB versions, including the new InfluxDB 3.0 product line via InfluxDB Community, currently in development.
  • AWS and InfluxData will also collaborate to offer AWS customers additional modules specific to the 3.0 product offering.

Agilent Presents 2024 Darlene Solomon Award to University of Cambridge Researcher Joycelyn Tan

Retrieved on: 
Thursday, March 14, 2024
Software, Research, Hardware, Electronic Design Automation, Consumer Electronics, Consumer, Technology, University, Health Technology, Education, Science, Women, Health, Metabolism, Obesity, Environment, Travel, Fazakerley, Female, Systems biology, Wellcome, Lipidomics, National university, Mass spectrometry, Woman, Doctor of Philosophy, Agilent Technologies, Behavior, DSM-IV codes, Pharmaceutical industry

Agilent Technologies Inc. (NYSE: A) announced today that Joycelyn Tan, a Ph.D. student at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge , UK, has been awarded the 2024 Darlene Solomon Award .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) announced today that Joycelyn Tan, a Ph.D. student at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge , UK, has been awarded the 2024 Darlene Solomon Award .
  • “I am grateful to receive this award from Agilent and FeMS,” said Ms. Tan.
  • Additionally, she will have the opportunity to visit the Agilent Global Solutions Development Center in Singapore, where she will work alongside Agilent scientists.
  • The Darlene Solomon Award is co-sponsored by FeMS (Females in Mass Spectrometry) and Agilent Technologies.

Mogo launches new Moka.ai investing app designed to help the next generation of Canadians become millionaires

Retrieved on: 
Thursday, March 14, 2024
Apps, Applications, Technology, Payments, Finance, Fintech, Banking, Professional Services, Software, Asset Management, Projection, Inc., Knowledge, AI, Diet, App Store (iOS/iPadOS), TSX, Behavior, Google Play, Investment, Index, Retirement, Artificial intelligence, Multimedia, Tree, Wildfire

“Our goal is to help ensure that the next generation doesn’t suffer the same fate.

Key Points: 
  • “Our goal is to help ensure that the next generation doesn’t suffer the same fate.
  • Moka makes it easy.”
    The new Moka.ai app includes a powerful combination of features to help Canadians simplify and automate the wealth-building process.
  • The app also allows for fractional investing; Moka users can easily customize the amount they want to contribute.
  • Canadians can open a Moka.ai account today by downloading the app: App Store and Google Play .

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Wednesday, March 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

New Report Reveals How Retirement Plan Design Can Address the Racial and Gender Retirement Savings Gap

Retrieved on: 
Tuesday, March 19, 2024
Other Consumer, Personal Finance, Women, Seniors, Finance, Consulting, Men, Professional Services, Consumer, Asset Management, Risk management, Retirement, Policy, Policy studies, Behavior, Gender, Multimedia, Probability, Aspen Institute, Bank

The Collaborative for Equitable Retirement Savings today published its first report, “ Racial and Gender Disparities in 401(k) Account Balances: How Large are They and What is Causing Them?

Key Points: 
  • The Collaborative for Equitable Retirement Savings today published its first report, “ Racial and Gender Disparities in 401(k) Account Balances: How Large are They and What is Causing Them?
  • Additional findings from the first report include:
    Black and Hispanic females contribute lower percentages of their salaries than their counterparts after controlling for age, salary, tenure, and plan design variables.
  • Examining the retirement savings data, and the underlying behaviors, around the existing disparities has unveiled preliminary insights that will help the retirement savings system evolve to address the racial and gender wealth gap,” said Lew Minsky, president and chief executive officer of DCIIA.
  • “This report signals that minor plan and benefit changes can likely translate to significant increases in the retirement savings balances of Black and Hispanic households in particular.

Emotional Link LLC CEO Naoto Sato Interviews Dr. Dan Ariely, Duke University, on "Wiser Spending Habits"

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Marketing, Education, Communications, Consulting, University, Dai, Privacy, The New York Times, Upside, Business, Duke University, Magic, Behavior, Left, Human, Student, Commerce, Psychology, Keio University, Predictably Irrational, Sense, Pain, Multimedia, Dis, Economics, Emotion, Flower

Emotional Link LLC , a business information dissemination company based in Minato Ward, Tokyo, has released an interview article with Professor Dan Ariely, Duke University, on "Wiser Spending Habits”.

Key Points: 
  • Emotional Link LLC , a business information dissemination company based in Minato Ward, Tokyo, has released an interview article with Professor Dan Ariely, Duke University, on "Wiser Spending Habits”.
  • The article , which is available on the Emotional Link LLC website, specifically targeting business professionals and students aspiring entrepreneurs interested in marketing, delves into people's spending tendencies and encourages wise spending habits based on them.
  • View the full release here: https://www.businesswire.com/news/home/20240312892584/en/
    Dr. Dan Ariely (Left) / Mr. Naoto Sato (Right) (Photo: Business Wire)
    For humans, it may be difficult to make rational decisions when spending money.
  • Naoto Sato is the CEO of Emotional Link LLC.

Grafana Labs Announces Updates to Kubernetes Monitoring Solution, Open Source Innovations, and Findings from 2024 Observability Survey

Retrieved on: 
Tuesday, March 12, 2024
Technology, Other Technology, Cloud, InfluxDB, Alert messaging, Namespace, ClickHouse, Health, Organization, Documentation, IBM Cloud, Observability, Pains, Memory, Machine, Presto, Container, AWS, CNCF, Telemetry, Cluster, Behavior, Software engineering, Ecosystem, EKS, Semantics, Helm, EBPF, CPU, The Pods, Video game

The company also released the findings from its second annual Observability Survey which provides insight into the evolving observability market.

Key Points: 
  • The company also released the findings from its second annual Observability Survey which provides insight into the evolving observability market.
  • With the new Grafana Kubernetes Monitoring Helm chart, it’s easier to send metrics, logs, events, traces, and cost metrics to Grafana Cloud.
  • Kubernetes support in Beyla : Grafana Labs’ 2024 Observability Survey found that eBPF is one of the technologies respondents are most excited about.
  • Grafana Operator migration : Grafana Operator, the open source Kubernetes operator that helps you manage your Grafana instances within and outside of Kubernetes, will now officially be managed by Grafana Labs.